147 related articles for article (PubMed ID: 11486986)
1. New guidelines for managing hypercholesterolemia.
McKenney JM
J Am Pharm Assoc (Wash); 2001; 41(4):596-607. PubMed ID: 11486986
[TBL] [Abstract][Full Text] [Related]
2. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines.
Grundy SM; Cleeman JI; Merz CN; Brewer HB; Clark LT; Hunninghake DB; Pasternak RC; Smith SC; Stone NJ;
J Am Coll Cardiol; 2004 Aug; 44(3):720-32. PubMed ID: 15358046
[TBL] [Abstract][Full Text] [Related]
3. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines.
Grundy SM; Cleeman JI; Merz CN; Brewer HB; Clark LT; Hunninghake DB; Pasternak RC; Smith SC; Stone NJ;
Arterioscler Thromb Vasc Biol; 2004 Aug; 24(8):e149-61. PubMed ID: 15297292
[TBL] [Abstract][Full Text] [Related]
4. Comparison of treatment with fluvastatin extended-release 80-mg tablets and immediate-release 40-mg capsules in patients with primary hypercholesterolemia.
Isaacsohn JL; LaSalle J; Chao G; Gonasun L
Clin Ther; 2003 Mar; 25(3):904-18. PubMed ID: 12852707
[TBL] [Abstract][Full Text] [Related]
5. New therapeutic options in the National Cholesterol Education Program Adult Treatment Panel III.
Talbert RL
Am J Manag Care; 2002 Sep; 8(12 Suppl):S301-7. PubMed ID: 12240701
[TBL] [Abstract][Full Text] [Related]
6. New features of the National Cholesterol Education Program Adult Treatment Panel III lipid-lowering guidelines.
Brewer HB
Clin Cardiol; 2003 Apr; 26(4 Suppl 3):III19-24. PubMed ID: 12708635
[TBL] [Abstract][Full Text] [Related]
7. Results of the National Cholesterol Education (NCEP) Program Evaluation ProjecT Utilizing Novel E-Technology (NEPTUNE) II survey and implications for treatment under the recent NCEP Writing Group recommendations.
Davidson MH; Maki KC; Pearson TA; Pasternak RC; Deedwania PC; McKenney JM; Fonarow GC; Maron DJ; Ansell BJ; Clark LT; Ballantyne CM
Am J Cardiol; 2005 Aug; 96(4):556-63. PubMed ID: 16098311
[TBL] [Abstract][Full Text] [Related]
8. New National Cholesterol Education Program III guidelines for primary prevention lipid-lowering drug therapy: projected impact on the size, sex, and age distribution of the treatment-eligible population.
Fedder DO; Koro CE; L'Italien GJ
Circulation; 2002 Jan; 105(2):152-6. PubMed ID: 11790693
[TBL] [Abstract][Full Text] [Related]
9. Reaching goal in hypercholesterolaemia: dual inhibition of cholesterol synthesis and absorption with simvastatin plus ezetimibe.
Daskalopoulou SS; Mikhailidis DP
Curr Med Res Opin; 2006 Mar; 22(3):511-28. PubMed ID: 16574035
[TBL] [Abstract][Full Text] [Related]
10. Update on managing hypercholesterolemia. The new NCEP guidelines.
Kuhar MB
AAOHN J; 2002 Aug; 50(8):360-4. PubMed ID: 12227210
[TBL] [Abstract][Full Text] [Related]
11. Cholesterol: precursor to many lipid disorders.
Jones PH
Am J Manag Care; 2001 Aug; 7(9 Suppl):S289-98. PubMed ID: 11517815
[TBL] [Abstract][Full Text] [Related]
12. Management of hypercholesterolaemia in postmenopausal women.
Davidson MH; Maki KC; Karp SK; Ingram KA
Drugs Aging; 2002; 19(3):169-78. PubMed ID: 12027776
[TBL] [Abstract][Full Text] [Related]
13. Achieving National Cholesterol Education Program goals for low-density lipoprotein cholesterol in cardiac patients: importance of diet, exercise, weight control, and drug therapy.
Allison TG; Squires RW; Johnson BD; Gau GT
Mayo Clin Proc; 1999 May; 74(5):466-73. PubMed ID: 10319076
[TBL] [Abstract][Full Text] [Related]
14. AMG 145, a monoclonal antibody against PCSK9, facilitates achievement of national cholesterol education program-adult treatment panel III low-density lipoprotein cholesterol goals among high-risk patients: an analysis from the LAPLACE-TIMI 57 trial (LDL-C assessment with PCSK9 monoclonal antibody inhibition combined with statin thErapy-thrombolysis in myocardial infarction 57).
Desai NR; Giugliano RP; Zhou J; Kohli P; Somaratne R; Hoffman E; Liu T; Scott R; Wasserman SM; Sabatine MS
J Am Coll Cardiol; 2014 Feb; 63(5):430-3. PubMed ID: 24161333
[TBL] [Abstract][Full Text] [Related]
15. The National Cholesterol Education Program Adult Treatment Panel III guidelines.
Lipsy RJ
J Manag Care Pharm; 2003; 9(1 Suppl):2-5. PubMed ID: 14613351
[TBL] [Abstract][Full Text] [Related]
16. Rising to the challenge of the new NCEP ATP III guidelines: exceeding current therapeutic limitations.
Brewer HB
Am J Manag Care; 2002 Feb; 8(2 Suppl):S23-8; discussion S45-7. PubMed ID: 11855698
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic lifestyle changes and pharmaceutical care in the treatment of dyslipidemias in adults.
Lenz TL
J Am Pharm Assoc (2003); 2005; 45(4):492-9; quiz 500-2. PubMed ID: 16128506
[TBL] [Abstract][Full Text] [Related]
18. Update on the National Cholesterol Education Program Adult Treatment Panel III guidelines: getting to goal.
McKenney JM
Pharmacotherapy; 2003 Sep; 23(9 Pt 2):26S-33S. PubMed ID: 14524636
[TBL] [Abstract][Full Text] [Related]
19. An evidence-based assessment of the NCEP Adult Treatment Panel II guidelines. National Cholesterol Education Program.
Ansell BJ; Watson KE; Fogelman AM
JAMA; 1999 Dec; 282(21):2051-7. PubMed ID: 10591388
[TBL] [Abstract][Full Text] [Related]
20. A community-based, randomized trial of ezetimibe added to statin therapy to attain NCEP ATP III goals for LDL cholesterol in hypercholesterolemic patients: the ezetimibe add-on to statin for effectiveness (EASE) trial.
Pearson TA; Denke MA; McBride PE; Battisti WP; Brady WE; Palmisano J
Mayo Clin Proc; 2005 May; 80(5):587-95. PubMed ID: 15887425
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
